2023
An Evaluation of Sex-Based Differences in Surrogate Consent for Older Adults Undergoing Surgical Intervention
Nagarkatti N, Miller S, Ahuja V, Schneider E, Mohanty S, Kodadek L. An Evaluation of Sex-Based Differences in Surrogate Consent for Older Adults Undergoing Surgical Intervention. Journal Of Surgical Research 2023, 288: 246-251. PMID: 37030182, DOI: 10.1016/j.jss.2023.02.041.Peer-Reviewed Original ResearchConceptsPreoperative cognitive impairmentMale patientsCognitive impairmentSurrogate consentSurgeons National Surgical Quality Improvement ProgramNational Surgical Quality Improvement ProgramSurgical Quality Improvement ProgramPatients age 65Preoperative cognitive statusQuality Improvement ProgramHigh rateSex-based differencesFemale patientsPatient sexSurgical interventionStratified analysisFacets of medicineAge 75American CollegePatientsAge 65Cognitive statusDescriptive studyOlder adultsAge categories
2022
Surrogate consent for surgery among older adult patients
Miller SM, Nagarkatti N, Ahuja V, Schneider EB, Mohanty S, Rosenthal RA, Kodadek LM. Surrogate consent for surgery among older adult patients. Surgery 2022, 172: 1748-1752. PMID: 36123180, DOI: 10.1016/j.surg.2022.08.015.Peer-Reviewed Original ResearchConceptsHalf of patientsCognitive impairmentSurrogate consentHigher comorbidity burdenOlder adult patientsComorbidity burdenPreoperative disabilityAdult patientsOlder patientsFemale patientsSurgical interventionElective proceduresSurgical proceduresHealth characteristicsAmerican CollegeDaily livingOwn consentPatientsOlder adultsImpairmentSurgeryConsentDescriptive analysisFurther researchDiagnosis
2021
A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793).
Roque D, Bellone S, Siegel E, Buza N, Bonazzoli E, Guglielmi A, Zammataro L, Nagarkatti N, Zaidi S, Lee J, Schwartz P, Ratner E, Alexandrov L, Iwasaki A, Kong Y, Song E, Dong W, Elvin J, Choi J, Santin A. A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793). Journal Of Clinical Oncology 2021, 39: 5523-5523. DOI: 10.1200/jco.2021.39.15_suppl.5523.Peer-Reviewed Original ResearchObjective response rateImmune checkpoint inhibitorsEndometrial cancer patientsTumor mutational burdenCancer patientsGrade 3/4 treatment-related adverse eventsSolid Tumors version 1.1Treatment-related adverse eventsSporadic tumorsPhase II pilot studyOverall survival proportionPrimary end pointResponse Evaluation CriteriaPhase II evaluationAntigen processing/presentationProcessing/presentationAdverse eventsICI resistancePrognostic significanceMechanisms of resistancePolymerase chain reactionII evaluationClinical studiesMutational burdenPatientsA phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793)
Bellone S, Roque DM, Siegel ER, Buza N, Hui P, Bonazzoli E, Guglielmi A, Zammataro L, Nagarkatti N, Zaidi S, Lee J, Silasi D, Huang GS, Andikyan V, Damast S, Clark M, Azodi M, Schwartz PE, Tymon-Rosario J, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Alexandrov LB, Iwasaki A, Kong Y, Song E, Dong W, Elvin J, Choi J, Santin AD. A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793). Annals Of Oncology 2021, 32: 1045-1046. PMID: 33932502, PMCID: PMC9465821, DOI: 10.1016/j.annonc.2021.04.013.Commentaries, Editorials and Letters